Emergent BioSolutions Inc.

Drug pipeline (6)

Asset	Stage	Revenue	Trials	Status
Boron	approved	—	4	approved
NALOXONE HYDROCHLORIDE	approved	—	0	—
RAXIBACUMAB	approved	—	1	approved
SOMATROPIN	approved	—	60	approved
BRINCIDOFOVIR	phase2	—	4	completed, withdrawn

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (36)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT05142306	phase1	completed	2021-12-07	2022-03-28	Emergent BioSolutions	A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
NCT04661839	phase1	completed	2020-12-24	2021-07-27	Emergent BioSolutions	A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
NCT01979406	phase1	completed	2013-11-01	2014-10-01	Emergent BioSolutions	A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
NCT01770743	phase2	completed	2013-01-01	2014-02-01	Emergent BioSolutions	A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
NCT03160339	phase1	terminated	2017-05-01	2017-11-27	Emergent BioSolutions	A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

FDA applications (13)

Application

Type

Applicant

Products

BLA 021538

BLA

Emergent Biosolutions Canada Inc.

BLA 103820

BLA

Emergent BioDefense Operations Lansing LLC

BLA 103821

BLA

Emergent BioDefense Operations Lansing LLC

BLA 125109

BLA

Emergent BioSolutions Canada Inc.

BLA 125158

BLA

Emergent Product Development Gaithersburg, Inc.